A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy

Gynecologic Oncology

Volumn 104, Issue 3, 2007, Pages 591-595

  Spannuth, Whitney A ^a   Leath III, Charles A ^a   Huh, Warner K ^a   Barnes III, Mack N ^a   Davidson, Susan A ^b   Kilgore, Larry C ^a   Partridge, Edward E ^a   Austin Jr , J Maxwell ^a   Alvarez, Ronald D ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Chemotherapy; Novel treatment regimens; Phase II study; Recurrent ovarian carcinoma; Topotecan

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; DOXORUBICIN; PLATINUM; TAMOXIFEN; TOPOTECAN;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; ASCITES; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DISEASE COURSE; DISEASE DURATION; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; EPITHELIUM; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOOT PAIN; GYNECOLOGIC SURGERY; HUMAN; LEUKOPENIA; MULTIPLE CYCLE TREATMENT; MUSCLE CRAMP; NAUSEA; OVARY CARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; THERAPY DELAY; THROMBOCYTOPENIA; TREATMENT OUTCOME; VAGINA BLEEDING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; EPITHELIAL CELLS; FEMALE; HUMANS; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; TOPOTECAN;

EID: 33846899996     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.09.008     Document Type: Article

References (21)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J. Clin. 56 2 (2006) 106-130
2. McGuire W.P., Hoskins W.J., Brady M.F., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334 1 (1996) 1-6
3. Ozols R.F., Bundy B.N., Greer B.E., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21 17 (2003) 3194-3200
4. Pfisterer J., Vergote I., Du Bois A., and Eisenhauer E. Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer. Int. J. Gynecol. Cancer 15 Suppl. 1 (2005) 36-41
5. Parmar M.K., Ledermann J.A., Colombo N., et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361 9375 (2003) 2099-2106
6. Markman M., Markman J., Webster K., et al. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J. Clin. Oncol. 22 15 (2004) 3120-3125
7. Gore M., ten Bokkel Huinink W., Carmichael J., et al. Clinical evidence for topotecan-paclitaxel non-cross-resistance in ovarian cancer. J. Clin. Oncol. 19 7 (2001) 1893-1900
8. Kita T., Kikuchi Y., Takano M., et al. The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer. Gynecol. Oncol. 92 3 (2004) 813-818
9. Markman M. Why study third-, fourth-, fifth-, ...line chemotherapy of ovarian cancer?. Gynecol. Oncol. 83 3 (2001) 449-450
10. Bookman M.A., Malmstrom H., Bolis G., et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J. Clin. Oncol. 16 10 (1998) 3345-3352
11. McGuire W.P., Blessing J.A., Bookman M.A., Lentz S.S., and Dunton C.J. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group Study. J. Clin. Oncol. 18 5 (2000) 1062-1067
12. Swisher E.M., Mutch D.G., Rader J.S., Elbendary A., and Herzog T.J. Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynecol. Oncol. 66 3 (1997) 480-486
13. Creemers G.J., Bolis G., Gore M., et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J. Clin. Oncol. 14 12 (1996) 3056-3061
14. Wall J.G., Burris III H.A., Von Hoff D.D., et al. A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days. Anti-cancer Drugs 3 4 (1992) 337-345
15. van Warmerdam L.J., ten Bokkel Huinink W.W., Rodenhuis S., et al. Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion. J. Clin. Oncol. 13 7 (1995) 1768-1776
16. Brown III J.V., Peters III W.A., Rettenmaier M.A., et al. Three-consecutive-day topotecan is an active regimen for recurrent epithelial ovarian cancer. Gynecol. Oncol. 88 2 (2003) 136-140
17. Homesley H., Benigno B., Williams J., and Vaccarello L. A phase I study of weekly topotecan and Paclitaxel in previously treated epithelial ovarian carcinoma patients. Gynecol. Oncol. 87 2 (2002) 171-177
18. Homesley H.D., Hall D.J., Martin D.A., et al. A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients. Gynecol. Oncol. 83 2 (2001) 394-399
19. Levy T., Inbar M., Menczer J., Grisaru D., Glezerman M., and Safra T. Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer. Gynecol. Oncol. 95 3 (2004) 686-690
20. Bhoola S.M., Coleman R.L., Herzog T., et al. Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer. Gynecol. Oncol. 95 3 (2004) 564-569
21. O'Malley D.M., Azodi M., Makkenchery A., et al. Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma. Gynecol. Oncol. 98 2 (2005) 242-248